Blockchain Registration Transaction Record

Soligenix Advances Rare Disease Treatments with HyBryte(TM) Platform

Soligenix Inc. advances rare disease treatments with HyBryte(TM) for CTCL and expands into psoriasis and COVID-19 vaccines, addressing critical unmet medical needs.

This news is crucial as it highlights Soligenix's innovative approach to treating rare diseases, particularly those affecting the aging population, which often lacks effective therapies. The development of HyBryte(TM) for CTCL and other conditions represents a beacon of hope for millions of patients and their families, offering potential new treatments where few exist. Additionally, Soligenix's work on vaccines for COVID-19 and other public health threats underscores the company's role in addressing global health challenges, making this news relevant not just to patients and healthcare providers, but to society at large.